Morning Overview on MSN
A blood test caught 90% of aggressive prostate cancers, against 74% for the standard PSA
The standard PSA test has anchored prostate cancer screening for decades, but it has a well-known weakness: it flags plenty ...
Morning Overview on MSN
The FDA cleared its first blood test to flag prostate cancer in men with high PSA
An elevated PSA reading has long put men in an uncomfortable position: it signals possible prostate cancer, but it is ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. This voice experience is generated by AI. Learn more. This voice ...
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results